Quantumzyme Corp. (OTC: QTZM), a biotechnology firm focused on computational enzyme engineering, has successfully had the 'Caveat Emptor' designation removed by OTC Markets Group, reclassifying it as a Current Information issuer with a Verified Profile. This achievement underscores the company's compliance with the OTCID disclosure framework, following its adoption of enhanced disclosure practices, updated financial reports, and measures to ensure corporate transparency. The company has also engaged securities counsel to maintain regulatory adherence.
Naveen Kulkarni, CEO of Quantumzyme, highlighted the company's dedication to transparency and the integrity of the market, noting that the removal of the warning enables a renewed focus on business strategy and enhancing shareholder value. Quantumzyme has also taken steps to address previous unauthorized promotional activities, clearly stating its non-involvement and disapproval of such actions, and has cooperated fully with related investigations. For more information, stakeholders are encouraged to visit the company's website and its profile on OTC Markets.
